Presbia Revenue and Competitors

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Presbia's estimated annual revenue is currently $5.3M per year.(i)
  • Presbia's estimated revenue per employee is $251,000

Employee Data

  • Presbia has 21 Employees.(i)
  • Presbia grew their employee count by -25% last year.

Presbia's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Manufacturing ManagerReveal Email/Phone
3
Executive chairman & CEOReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$20.3M817%N/AN/A
#2
$8.5M346%N/AN/A
#3
$4.5M18-10%N/AN/A
#4
$8M32-6%N/AN/A
#5
$5.3M210%N/AN/A
#6
$54.2M2169%N/AN/A
#7
$12M48N/AN/AN/A
#8
$10M405%N/AN/A
#9
$30.1M12022%N/AN/A
#10
$14.1M562%N/AN/A
Add Company

What Is Presbia?

Presbia is a medical device company focused on the development of the presbyopia-correcting Presbia Flexivue Microlens™ – an innovative solution for the common age-related loss of the ability to read or focus on near objects. The 3mm diameter lens is implanted in a corneal pocket created by a femtosecond laser.

keywords:N/A

N/A

Total Funding

21

Number of Employees

$5.3M

Revenue (est)

-25%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Presbia News

2022-04-20 - Global Presbyopia Correction Devices Market 2022 – Analysis ...

Presbia. Geographically, the resulting regions, as well as the national/local markets registered below, are thoroughly investigated: North America (United...

2022-04-19 - Corneal Implants Market Size 2022-2029| Key Players ...

Neoptics; ReVision Optics; AcuFocus; Presbia; KeraMed; Powervision; Cornea Research Foundation of America; Ocular Systems; Cornea Biosciences; DIOPTEX; SMR...

2022-04-06 - Presbyopia Correction Devices Market Size, Scope And ...

Presbyopia Correction Devices Market Size, Scope And Forecast | Leading Players – AcuFocus, Refocus, Presbia, AcuFocus.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.1M21N/AN/A
#2
$4M21-34%N/A
#3
$2.1M21-22%N/A
#4
$3M21-12%N/A
#5
$3.3M21-12%N/A